| Product Code: ETC7657614 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Oncogene Inhibitors Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Oncogene Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Oncogene Inhibitors Market - Industry Life Cycle |
3.4 Israel Oncogene Inhibitors Market - Porter's Five Forces |
3.5 Israel Oncogene Inhibitors Market Revenues & Volume Share, By Genes, 2021 & 2031F |
3.6 Israel Oncogene Inhibitors Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Israel Oncogene Inhibitors Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.8 Israel Oncogene Inhibitors Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Israel Oncogene Inhibitors Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 Israel Oncogene Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Oncogene Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Israel |
4.2.2 Growing investments in oncology research and development |
4.2.3 Technological advancements in oncogene inhibitor therapies |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approvals |
4.3.2 High costs associated with oncogene inhibitor treatments |
4.3.3 Limited availability of skilled healthcare professionals in oncology |
5 Israel Oncogene Inhibitors Market Trends |
6 Israel Oncogene Inhibitors Market, By Types |
6.1 Israel Oncogene Inhibitors Market, By Genes |
6.1.1 Overview and Analysis |
6.1.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Genes, 2021- 2031F |
6.1.3 Israel Oncogene Inhibitors Market Revenues & Volume, By EGFR, 2021- 2031F |
6.1.4 Israel Oncogene Inhibitors Market Revenues & Volume, By HER, 2021- 2031F |
6.1.5 Israel Oncogene Inhibitors Market Revenues & Volume, By BRCA, 2021- 2031F |
6.1.6 Israel Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Oncogene Inhibitors Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.3 Israel Oncogene Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.4 Israel Oncogene Inhibitors Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.2.5 Israel Oncogene Inhibitors Market Revenues & Volume, By Pancreas Cancer, 2021- 2031F |
6.2.6 Israel Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Oncogene Inhibitors Market, By Treatment |
6.3.1 Overview and Analysis |
6.3.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Platinum-Based Chemotherapy, 2021- 2031F |
6.3.3 Israel Oncogene Inhibitors Market Revenues & Volume, By PARP Inhibitors, 2021- 2031F |
6.3.4 Israel Oncogene Inhibitors Market Revenues & Volume, By Anti-HER Antibodies, 2021- 2031F |
6.3.5 Israel Oncogene Inhibitors Market Revenues & Volume, By EFGR Inhibitors, 2021- 2031F |
6.3.6 Israel Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Israel Oncogene Inhibitors Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Israel Oncogene Inhibitors Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.5 Israel Oncogene Inhibitors Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Israel Oncogene Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.4 Israel Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Israel Oncogene Inhibitors Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Israel Oncogene Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Israel Oncogene Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 Israel Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Oncogene Inhibitors Market Import-Export Trade Statistics |
7.1 Israel Oncogene Inhibitors Market Export to Major Countries |
7.2 Israel Oncogene Inhibitors Market Imports from Major Countries |
8 Israel Oncogene Inhibitors Market Key Performance Indicators |
8.1 Clinical trial success rates for oncogene inhibitor therapies |
8.2 Adoption rates of personalized medicine approaches in oncology |
8.3 Number of research publications on oncogene inhibitors in Israel |
8.4 Patient outcomes and survival rates post-treatment with oncogene inhibitors |
8.5 Investment trends in oncogene inhibitor research and development |
9 Israel Oncogene Inhibitors Market - Opportunity Assessment |
9.1 Israel Oncogene Inhibitors Market Opportunity Assessment, By Genes, 2021 & 2031F |
9.2 Israel Oncogene Inhibitors Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Israel Oncogene Inhibitors Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.4 Israel Oncogene Inhibitors Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Israel Oncogene Inhibitors Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 Israel Oncogene Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Oncogene Inhibitors Market - Competitive Landscape |
10.1 Israel Oncogene Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 Israel Oncogene Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here